Abnormal fibrin clot architecture in nephrotic patients is related to hypofibrinolysis: Influence of plasma biochemical modifications. A possible mechanism for the high thrombotic tendency?

Thrombosis and Haemostasis

Volumn 82, Issue 5, 1999, Pages 1482-1489

  Collet, Jean Philippe ^a   Mishal, Zohar ^b   Lesty, Claude ^d   Mirshahi, Manoucher ^a   Peynet, Jacqueline ^d   Baumelou, Alain ^d   Bensman, Albert ^c   Soria, Jeannette ^a   Soria, Claudine ^d  

^a HÔTEL DIEU   (France)

^b CNRS   (France)

^c ARMAND TROUSSEAU HOSPITAL   (France)

^d NONE

Author keywords

Fibrin; Hypofibrinolysis; Nephrotic syndrome

Indexed keywords

ALBUMIN; FIBRIN; FIBRINOGEN; FIBRINOLYTIC AGENT; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HUMAN; MORPHOLOGY; NEPHROTIC SYNDROME; PATHOPHYSIOLOGY; POROSITY; PRIORITY JOURNAL; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VISCOELASTICITY;

EID: 0032728127     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614859     Document Type: Article

References (36)

1. Llach F. Hypercoagulability, renal vein thrombosis, and other thrombotic complications of nephrotic syndrome. Kidney Int 1985; 28: 429-39.
2. Robert A, Olmer M, Sampol J, et al. Clinical correlation between hypercoagulability and thromboembolic phenomena. Kidney Int 1987; 31: 830-5.
3. Sagripanti A, Barsotti G. Hypercoagulability, intraglomerular coagulation, and thromboembolism in nephrotic syndrome. Nephron 1995; 70: 271-81.
4. Weisel JW, Nagaswami C. Computer modeling of fibrin polymerization kinetics correlated with electron microscope and turbidity observations: clot structure and assembly are kinetically controlled. Biophys J 1992; 60: 111-29.
5. Blombäck B, Carlsson K, Fatah K, Banerjee D, Hessel B, Procyck R. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-38.
6. Blombäck B, Banerjee D, Carlsson K, Hamsted A, Hessel B, Zarchaskil. Native fibrin gel networks and factors influencing their formation in health disease. In: Fibrinogen, Thrombosis, Coagulation and Fibrinolysis. Liu CY, Chien S, eds, New York: Plenum Press 1992; pp 1-23.
7. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-43.
8. Blombäck B, Carlsson K, Hessel B, Liljeborg A, Procyck R, Aslund N. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Bioch Biophys Acta 1989; 997: 96-110.
9. Carr ME, Shen L, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16: 1-15.
10. Janmey P. A torsion pendulum for measurement of the viscoelasticity of biopolymers and its application to actin networks. J Bioch Bioph Met 1991; 22: 41-53.
11. Lesty M, Buat-Ménard P. La synthèse géométrique des correlations multidimensionnelles. In Cahiers Annal Données. Eds Dunod. Paris, 1982; pp. 355-70.
12. Lesty C, Raphael M, Nonnenmacher L, Binet JL. Two statistical approaches for nuclei shape and size in a morphometric description of lymph node sections in non-Hodgkin's lymphoma. Cytometry 1989; 10: 28-36.
13. Lesty C, Cleq C, Contesso G, Jacquillat C. Nucleoli and AgNor proteins in 32 cases of primary breast carcinoma. Spatial pattern of interactions between 50 clinical and histometric criteria. Analyt Quant Cytol Histol 1992; 14: 175-86.
14. Allison PD. Survival analysis using the SASR system: A practical guide. Gary, NC: SAS Institute Inc. 1995; p. 292.
15. Carr ME. Fibrin formed in plasma is composed of fibers more massive than those formed from purified fibrinogen. Thromb Haemost 1988; 59: 535-9.
16. Nair CH, Dhall DP. Studies on fibrin network structure: the effect of some plasma proteins. Thromb Res 1991; 61: 315-25.
17. Collet JP, Soria J, Mirshahi Mc, Hirsh M, Dagonnet FB, Caen J, Soria C. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: Hypofibrinolysis related to an abnormal clot structure. Blood 1993; 82: 2462-9.
18. Abshire TC, Fink LK. The prolonged thrombin time of nephrotic syndrome. Journal of Pediatric Hematology/Oncology. 1995; 17: 156-62.
19. Carr ME. Turbidimetric evaluation of the impact of albumin on the structure of thrombin-mediated fibrin gelation. Haemostasis 1987; 17: 189-94.
20. Torbet J. Fibrin assembly in human plasma and fibrinogen/albumin mixtures. Biochemistry 1988; 25: 5309-14.
21. Laurent TC. An early look at macromolecular crowding. Biophys Chem 1995; 57: 7-14.
22. Galanakis DK, Lane BP, Simon SR. Albumin modulates lateral assembly of fibrin polymers: evidence of enhanced fine fibril formation and unique synergism with fibrinogen. Biochemistry 1987; 26: 2389-400.
23. Gandrille S, Aiach M. Albumin concentration influences fibrinolytic activity in plasma and purified system. Fibrinolysis 1990; 4: 225-32.
24. Gandrille S, Jouvin MH, Toulon P, Remy P, Fiessinger JN, Roncato M, Moatti N, Aiach M. A study of fibrinogen and fibrinolysis in 10 adults with nephrotic syndrome. Thromb Haemost 1988; 59: 445-50.
25. Diamond SL, Anand S. Inner clot diffusion and permeation during fibrinolysis. Biophys J 1993; 65: 2622-43.
26. Weitz JI, Leslie B, Huboda M. Thrombin binds to soluble degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97: 544-52.
27. Carr ME, Alving BM. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots. Blood Coag Fibrinolysis 1995; 6: 567-73.
28. Don A Gabriel, Muga K, Boothroyd EM. The effect of fibrin structure on fibrinolysis. J Biol Chem 1992; 267 (34): 24259-63.
29. Mc Donagh. Suppression of plasminogen binding to fibrin by high fibrinogen: A mechanism for how fibrinogen enhances the risk of thrombosis. Thrombosis. Sanofi Association for Thrombosis Research 1994; 4: No 1, I-XX.
30. Kline A, Hughes LE, Campbell H et al. Dextran 70 in prophylaxis of thromboembolic disease after surgery: a clinically oriented randomized double blind trial. BMJ 1975; 2: 109-12.
31. Gruber UF, Saldeen T, Brokop T et al. Incidences of fatal postoperative pulmonary embolism after prophylaxis of thromboembolic with dextran or low-dose heparin: an international multicentre study. BMJ 1980; 280: 69-72.
32. Matthiasson S, Lindblad B, Mätzsch T, Holst J, Bergqvist D. Effect of low molecular weight heparin, dextran and their combinations on experimental venous thrombosis in rabbits. Thromb Haemost 1994; 71: 363-5.
33. Matthiasseon S, Lindblad B, Mätzsch T, Molin J, Quarford P, Bergqvist D. Study of the interaction of dextran and enoxaparin on haemostasis in humans. Thromb Haemost 1994; 72: 722-7.
34. Ordonez BW, Hiat R, Killebrew E, Fireman B. The risk of coronary artery disease among patients with nephrotic syndrome. Kidney Int 1990; 37: 243A.
35. Mallick NP, Short CD. The nephrotic syndrome and ischemic heart disease. Nephron 1981; 27: 58-61.
36. Fatah K, Silveira A, Tornvall P, Karpe F, Blombäck M, Hamsten A. Proneness to formation of tight and rigid fibrin gel structures in men with acute myocardial infarction at a young age. Thromb Haemost 1996; 76: 535-41.